Takeda has entered into an agreement to divest its portfolio of five pharmaceutical products, mostly prescription assets sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica and Panama, as well as in other countries in Central America and the Caribbean to Adium, subject to customary legal and regulatory closing conditions. 'Pursuant to this agreement, Takeda will keep on developing and supplying the products object to this contract for the next five years to Adium, in line with the Company's purpose to provide better health for people and a brighter future for the world.'. 'The divestment reinforces Takeda's commitment to deliver highly innovative products by sharpening our focus on our five strategic business areas as part of our global strategy for long-term growth', stated Gabriela Pittis, president of the SAM area for Takeda's GEM BU. Furthermore, it helps Takeda achieve our ambition to become a global, value-based, R&D-driven biopharmaceutical leader.'Īdium, a pharmaceutical company founded in 1975 headquartered in Uruguay, operates in 18 Latin American countries, dedicated to the development, production and commercialization of pharmaceutical products, providing access to doctors and patients in Latin America, to innovative and quality treatments with a commercial portfolio that includes proprietary branded generics and innovative pharmaceutical licensed products in the areas of oncology, rheumatology, pain, urology, women's health, neurology, cardiology and gastroenterology. Through this divestment, we will have a greater ability to focus on strengthening our efforts in key therapeutic to meet the needs of patients living with a serious or rare disease. 'The strategy adopted by our GEM BU contributes to accelerate patients' sustainable access to innovation. 'We are confident that Adium is well-positioned to guarantee patients' continuous access to the products subject to this transaction,' said Ricardo Marek, president of Takeda's Growth & Emerging Markets (GEM) Business Unit (BU). Until then, Takeda remains the owner of these products and is responsible for ensuring patient access to them. The transaction is expected to close in the second half of 2021, subject to the satisfaction of customary closing conditions. Pantoprazole, Alevian, Dexlansoprazole, Riopan, Faktu.
The portfolio to be divested includes five non-core products mostly prescription gastroenterology assets: ('Adium'), subject to customary legal and regulatory closing conditions. BUENOS AIRES, Argentina, SeptemToday, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ('Takeda') announced that it has entered into an agreement to divest a selection of non-core products from the Company's portfolio sold in Argentina, Colombia, Ecuador, Peru, Guatemala, Costa Rica, Panama and other countries in Central America and the Caribbean that make up the South Cone, Andean Region, Mexico and Central America and Caribbean regions (SAM) in its Growth and Emerging Markets Business Unit (GEM BU) to Adium Pharma S.A.
0 kommentar(er)
